SUMMIT: tirzepatide lowered the risk of worsening heart failure

Fewer cardiovascular deaths or heart-failure worsening events than placebo, and better health status.

SUMMIT evaluated tirzepatide in people with heart failure with preserved ejection fraction and obesity, over a longer period than previous studies, with clinical outcomes rather than symptoms alone.

Tirzepatide lowered the risk of the composite of cardiovascular death or worsening heart failure versus placebo, and improved participant-reported health status.

In three points

Human trial with hard clinical outcomes
Lower risk of cardiovascular death or worsening
Better self-reported health status

Compounds mentioned

Tirzepatide

Original source: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.